Adma Biologics Shares Maintain Upward Momentum on Strong Financial Performance

Adma Biologics continues its impressive market run, building on recent gains with another strong trading session. The company's equity reached $14.52 at week's end, marking a 3.5% increase, and has demonstrated continued strength in subsequent trading.

The biotechnology firm delivered exceptional third-quarter 2025 results that underscore its operational strength:

• Revenue reached $134.2 million, representing 12% year-over-year growth
• GAAP net income totaled $36.4 million, a 1% improvement
• Adjusted EBITDA climbed to $58.7 million, surging 29% higher

A significant expansion in gross margin from 49.8% to 56.3% highlights enhanced operational efficiency. The company's flagship product, ASCENIV, achieved record utilization rates during the period.

Regulatory Milestone Enhances Production Capabilities

A pivotal development emerged as the FDA granted approval for the company's first yield-optimized production batches. This technological advancement is projected to substantially boost manufacturing efficiency beginning in the fourth quarter, providing additional margin expansion opportunities.

Should investors sell immediately? Or is it worth buying Adma Biologics?

Management Raises Guidance Substantially

Corporate leadership significantly upgraded future expectations, reflecting strong confidence in the company's trajectory:

• 2025 revenue forecast raised to at least $510 million
• 2026 revenue projection set at minimum $630 million
• 2026 adjusted EBITDA anticipated to exceed $355 million

Even more notably, the net income outlook for 2026 was lifted to over $255 million, representing a strong endorsement of the company's strategic direction.

Market analysts maintain positive ratings and optimistic price targets, with the SG-001 pipeline and anticipated reimbursement expansions beginning in 2026 supporting the long-term growth narrative. The biotechnology specialist appears well-positioned for its next phase of upward movement.